A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia

Trial Profile

A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Plasminogen (Primary)
  • Indications Type I plasminogen deficiency
  • Focus Registrational; Therapeutic Use
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 03 Apr 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 10 Jan 2018 Results of an interim analysis (n=14; Data cut-off: April 1, 2017) published in the Blood
    • 12 Dec 2017 Results (n=10) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top